Special Issue

Molecular and Cellular Mechanisms of Pancreatitis

Message from the Guest Editor

This Special Issue aims to discover and develop novel strategies or mechanisms, single compounds, natural products, or combination formulas with beneficial properties in various pancreatitis experimental models. Original research articles and reviews focused on molecular and cellular mechanisms are welcome. Topics of interest also include pharmacokinetics, metabolism, pharmacology, and toxicology related to the use of drugs in pancreatitis. While the focus of experimental drug mechanisms is primarily on the pharmacological research of new agents, novel pharmacodynamic and pharmacokinetic mechanisms that may explain or predict molecular and cellular mechanisms of acute and chronic pancreatitis already in use and/or provide potential targets for drug development are also welcome.

Guest Editor

Dr. Gi-Sang Bae

Department of Pharmacology, School of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea

Deadline for manuscript submissions

closed (30 September 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/171013

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).